209 related articles for article (PubMed ID: 33939422)
1. Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design.
Yan NL; Santos-Martins D; Nair R; Chu A; Wilson IA; Johnson KA; Forli S; Morgan GJ; Petrassi HM; Kelly JW
J Med Chem; 2021 May; 64(9):6273-6299. PubMed ID: 33939422
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins.
Yan NL; Santos-Martins D; Rennella E; Sanchez BB; Chen JS; Kay LE; Wilson IA; Morgan GJ; Forli S; Kelly JW
Bioorg Med Chem Lett; 2020 Aug; 30(16):127356. PubMed ID: 32631553
[TBL] [Abstract][Full Text] [Related]
3. Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site.
Yan NL; Nair R; Chu A; Wilson IA; Johnson KA; Morgan GJ; Kelly JW
Bioorg Med Chem Lett; 2022 Mar; 60():128571. PubMed ID: 35065233
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of amyloidogenic immunoglobulin light chains by small molecules.
Morgan GJ; Yan NL; Mortenson DE; Rennella E; Blundon JM; Gwin RM; Lin CY; Stanfield RL; Brown SJ; Rosen H; Spicer TP; Fernandez-Vega V; Merlini G; Kay LE; Wilson IA; Kelly JW
Proc Natl Acad Sci U S A; 2019 Apr; 116(17):8360-8369. PubMed ID: 30971495
[TBL] [Abstract][Full Text] [Related]
5. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
6. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
Klimtchuk ES; Gursky O; Patel RS; Laporte KL; Connors LH; Skinner M; Seldin DC
Biochemistry; 2010 Nov; 49(45):9848-57. PubMed ID: 20936823
[TBL] [Abstract][Full Text] [Related]
7. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis.
Yan NL; Morgan GJ; Petrassi HM; Wilson IA; Kelly JW
Curr Opin Chem Biol; 2023 Aug; 75():102319. PubMed ID: 37279624
[TBL] [Abstract][Full Text] [Related]
9. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
[TBL] [Abstract][Full Text] [Related]
10. The Antibody Light-Chain Linker Is Important for Domain Stability and Amyloid Formation.
Nokwe CN; Hora M; Zacharias M; Yagi H; John C; Reif B; Goto Y; Buchner J
J Mol Biol; 2015 Nov; 427(22):3572-3586. PubMed ID: 26408269
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.
Hora M; Carballo-Pacheco M; Weber B; Morris VK; Wittkopf A; Buchner J; Strodel B; Reif B
Sci Rep; 2017 Jan; 7():41515. PubMed ID: 28128355
[TBL] [Abstract][Full Text] [Related]
12. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
Morgan GJ
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
[TBL] [Abstract][Full Text] [Related]
13. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
14. Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?
Morgan GJ; Usher GA; Kelly JW
Biochemistry; 2017 Dec; 56(50):6597-6614. PubMed ID: 29200282
[TBL] [Abstract][Full Text] [Related]
15. The Antibody Light-Chain Linker Regulates Domain Orientation and Amyloidogenicity.
Weber B; Hora M; Kazman P; Göbl C; Camilloni C; Reif B; Buchner J
J Mol Biol; 2018 Dec; 430(24):4925-4940. PubMed ID: 30414962
[TBL] [Abstract][Full Text] [Related]
16. Unfolding and Aggregation Pathways of Variable Domains from Immunoglobulin Light Chains.
Meunier-Carmenate Y; Valdés-García G; Maya-Martinez R; French-Pacheco L; Fernández-Silva A; González-Onofre Y; Millan-Pacheco C; Pastor N; Amero C
Biochemistry; 2023 Mar; 62(5):1000-1011. PubMed ID: 36802343
[TBL] [Abstract][Full Text] [Related]
17. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
Kim YS; Cape SP; Chi E; Raffen R; Wilkins-Stevens P; Stevens FJ; Manning MC; Randolph TW; Solomon A; Carpenter JF
J Biol Chem; 2001 Jan; 276(2):1626-33. PubMed ID: 11050093
[TBL] [Abstract][Full Text] [Related]
18. Effects of oxidative post-translational modifications on structural stability and self-assembly of λ6 immunoglobulin light chain.
Zottig X; Laporte Wolwertz M; Golizeh M; Ohlund L; Sleno L; Bourgault S
Biophys Chem; 2016 Dec; 219():59-68. PubMed ID: 27744229
[TBL] [Abstract][Full Text] [Related]
19. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
20. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
